Combating Prostate Cancer with Advanced Diagnostics and Treatments
Chesapeake Urology treats one third of the prostate cancer patients in Maryland, and our prostate cancer specialists remain on the leading-edge of advanced treatments and diagnostics.
In fact, Chesapeake Urology is one of only a few medical groups in the country to offer the 3D Ultrasound/MRI Fusion Biopsy for Prostate Cancer, providing men with even more targeted prostate cancer diagnostics, leading to more precise treatment planning and better outcomes.
Chesapeake Urology offers the 3D Ultrasound/MRI Fusion Biopsy for Prostate Cancer which “fuses” detailed MRI scans with live, real-time ultrasound images of the prostate, providing urologists with the capabilities to pinpoint exact prostate cancer lesion location within the prostate gland and better identify the extent of disease. Led by Thomas Smyth, M.D., Chesapeake Urology has performed more than 700 of these biopsies since the first one was performed in 2014.
Clinical Research Leads to FDA Approval of New SpaceOAR Hydrogel System
Chesapeake Urology's Prostate Cancer Center was the lead clinical research site, led by Richard Hudes, M.D., that resulted in FDA approval of a new application called SpaceOAR® Hydrogel System. SpaceOAR helps prevent damage to the rectum due to potential "scatter" of radiation during radiation therapy for prostate cancer treatment. OAR stands for "Organs at Risk."
SpaceOAR hydrogel is injected between the prostate and rectum under ultrasound guidance. The special hydrogel then pushes the rectum away from the prostate. By separating the prostate from the rectum, SpaceOAR Hydrogel may eliminate or reduce damage to the rectum from radiation therapy and allow the urologist to enhance radiation treatment to the prostate to better target the cancer or even reduce the total number of treatment sessions. Learn more.
For in depth information on prostate cancer, please visit our prostate cancer website.